Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in children

Am J Ophthalmol. 2003 Jun;135(6):900-2. doi: 10.1016/s0002-9394(02)02224-9.

Abstract

Purpose: To report the safety of photodynamic therapy with verteporfin in three children.

Design: Retrospective interventional noncomparative case series.

Method: Children identified from all patients treated with verteporfin therapy at a university-based practice had records reviewed for adverse retinal or systemic events.

Results: Patients aged 11, 11, and 13 years, with subfoveal idiopathic choroidal neovascularization (CNV) received verteporfin therapy with no ocular complications recognized either immediately after the procedure or during the follow-up from 7 to 12 months. Treatment resulted in cessation of fluorescence leakage from CNV by the last follow-up visit in two patients and reduced leakage from the lesion in one. The visual acuity change was + 4, +7, and 0 lines.

Conclusions: Verteporfin therapy in three children with subfoveal CNV was associated with stable or improved vision during short-term follow-up in the absence of serious ocular or systemic adverse events.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Capillary Permeability
  • Child
  • Choroidal Neovascularization / drug therapy*
  • Fluorescein Angiography
  • Follow-Up Studies
  • Fovea Centralis / drug effects*
  • Humans
  • Photochemotherapy*
  • Photosensitizing Agents / therapeutic use*
  • Porphyrins / therapeutic use*
  • Retrospective Studies
  • Safety
  • Verteporfin
  • Visual Acuity

Substances

  • Photosensitizing Agents
  • Porphyrins
  • Verteporfin